All In Biotech

Drug Trial Radar · NCT00259610

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

Last checked: Nov 20, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 755 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

755

Actual

Start

May 2004

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amgen; Barr Laboratories; Pfizer
First posted
Nov 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better

Conditions

  • Rheumatoid Arthritis

Interventions

  • methotrexateDrug

    varies

  • sulfasalazineDrug

    varies

  • hydroxychloroquineDrug

    varies

  • etanerceptDrug

    varies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR)Time frame: Change of the Mean of DAS28-ESR between weeks 48 - 102.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.